Advertisements

gilead

Gilead Sciences shares gain after topping expectations despite lower remdesivir sales By Investing.com

by

[ad_1] © Reuters Gilead Sciences shares gain after topping expectations despite lower remdesivir sales By Sam Boughedda Gilead Sciences (NASDAQ:) shares rallied in early Friday trading in reaction to the company’s latest earnings report, which saw it beat top and bottom-line consensus expectations. The biopharmaceutical company posted fourth-quarter of $1.67 per share, $0.17 above the … Read more

Infographic: Highlights of Gilead Sciences (GILD) Q4 2022 earnings report

by

[ad_1] Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when its revenues moved up 2%. Revenues increased by 2% annually to $7.4 billion in the final three months of fiscal 2022. A 58% increase in international product sales more than offset weakness … Read more

Gilead profit beats Street expectations on COVID and HIV sales By Reuters

by

[ad_1] © Reuters. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam/File Photo By Michael Erman and Sriparna Roy (Reuters) -Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had … Read more